《大行報告》花旗升默沙東(MRK.US)評級至「買入」 目標價上調至130美元
花旗發表研究報告,將默沙東(MRK.US)的投資評級從「中性」上調至「買入」,並基於估值預測將目標價從105美元上調至130美元,看好公司旗下的ADC藥物MK-2870及SKB-264(TROP2),以及用於治療肺動脈高壓的藥物Sotatercept及新型降膽固醇藥物MK-0616的表現。
該行又指,投資者較少關注默沙東MRK通過與科倫博泰生物醫藥達成的ADC許可協議,預測公司2033年風險調整後銷售額將達到約60億美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.